Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8186
Title: Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer
Authors: Akça, Hakan
Demiray, Aydın
Yaren, Arzu
Bir, Ferda
Köseler, Aylin
Iwakawa, R.
Bağcı, Gülseren
Keywords: EGFR
Mutations
NSCLC
Serum DNA
Turkish
DNA
epidermal growth factor receptor
paraffin
adult
aged
article
cancer staging
controlled study
DNA determination
DNA isolation
DNA sequence
epidermal growth factor receptor gene
female
gene mutation
genetic association
human
human tissue
lung adenocarcinoma
lung non small cell cancer
lung squamous cell carcinoma
major clinical study
male
mutation rate
mutational analysis
point mutation
priority journal
pyrosequencing
single nucleotide polymorphism
tissue section
Adenocarcinoma
Aged
Base Sequence
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
DNA, Neoplasm
Female
Humans
Logistic Models
Lung Neoplasms
Male
Middle Aged
Multivariate Analysis
Mutation
Mutation Rate
Mutation, Missense
Neoplasm Staging
Neoplastic Cells, Circulating
Receptor, Epidermal Growth Factor
Sequence Analysis, DNA
Sequence Deletion
Abstract: Mutations in the EGFR gene are critical determinants of treatment with EGFR tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) patients. DNA isolation from tumor samples usually requires surgery; therefore, we wanted to isolate DNA from circulating tumor cells by using the serum of NSCLC patients. This protocol was recently published. DNA was isolated from the serum of 52 Turkish NSCLC patients and their EGFR mutation status was examined by pyrosequencing. EGFR mutations were detected in 25 of the 52 patients (48.1%): 17 patients with delE746-A750, 2 with delE747-A750insP, and 6 with L858R. All mutations detected by pyrosequencing were confirmed by dideoxy sequencing, and the presence of the same mutations in the tumors was verified by using paraffin embedded tissues of all the patients. Mutations were detected more frequently in adenocarcinomas (24 of 36, 66.7%) than in squamous cell carcinomas (1 of 16, 6.3%) (. P < 0.001). These results confirm the utility of serum DNA and pyrosequencing for the detection of EGFR mutations in patients with advanced NSCLC. © 2013 .
URI: https://hdl.handle.net/11499/8186
https://doi.org/10.1016/j.cancergen.2013.01.005
ISSN: 2210-7762
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

39
checked on Nov 30, 2024

WEB OF SCIENCETM
Citations

40
checked on Dec 1, 2024

Page view(s)

62
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.